<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03688971</url>
  </required_header>
  <id_info>
    <org_study_id>CLS001-CO-PR-017</org_study_id>
    <nct_id>NCT03688971</nct_id>
  </id_info>
  <brief_title>Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis</brief_title>
  <official_title>A Phase 2, Randomized, Vehicle and Ketoconazole-Controlled, Evaluator-Blinded, Study to Explore the Efficacy, Pharmacodynamics and Safety of Omiganan 1.75% Topical Gel BID in Patients With Mild to Moderate Facial Seborrheic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maruho Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maruho Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the efficacy and pharmacodynamic effects of omiganan topical gel in facial
      seborrheic dermatitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seborrheic dermatitis area severity index (SDASI)</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Assessment of erythema, scales and papules and each are scored as 0=none to 3=severe.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator global assessment (IGA)</measure>
    <time_frame>6 Weeks</time_frame>
    <description>This is a 5-point scale ranging from 0=clear to 4=severe.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area of involvement</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Facial area involvement is estimated as a % of the body surface area (BSA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported Outcome (PRO) - eDiary</measure>
    <time_frame>4 Weeks</time_frame>
    <description>Single-question assessment regarding patient's worst itch. On a scale of 0-100, 0=no itch and 100=worst itch.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PRO - 5-D itch scale</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Multidimensional measure of itching. Covers 5 domains: duration, degree, direction, disability and distribution.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PRO - dermatology life quality index (DLQI)</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Asses health-related quality of life in general dermatology disability index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standardized photography</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Facial photographs will be taken by a 2D camera (VISIA-CR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sebum measurements</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Measurement of sebum excretion by Sebumeter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trans Epidermal Water Loss (TEWL)</measure>
    <time_frame>6 Weeks</time_frame>
    <description>To assess barrier status of lesional and non-lesional skin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Optical Coherence Tomography (OCT)</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Measurement of cutaneous morphology of seborrheic dermatitis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liquid chromatography-mass spectrometry (LC-MS)</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Will evaluate the changes in lipid composition of stratum corneum (SC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skin microbiota</measure>
    <time_frame>6 Weeks</time_frame>
    <description>collection of skin culture sample to evaluate skin microbiota</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin mycobiota</measure>
    <time_frame>6 Weeks</time_frame>
    <description>collection of skin culture sample to evaluate skin mycobiota</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Faecal microbiome</measure>
    <time_frame>4 Weeks</time_frame>
    <description>collection of faecal samples to evaluate faecal microbiome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events collected throughout the study</measure>
    <time_frame>6 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs performed at screening and end of study</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Evaluation of systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs performed at screening and end of study</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Evaluation of pulse rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs performed at screening and end of study</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Evaluation of temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Lead ECGs performed at screening and end of study</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Assessment of heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Lead ECGs performed at screening and end of study</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Assessment of PR, QRS, QT, QTcB and QTcF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology blood sample assessment</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Evaluation of blood collected in BD Vacutainer K2EDTA tube.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemistry blood sample assessment</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Evaluation of blood collected in BD Vacutainer SST Gel and Clot Activator tube.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinalysis urine sample assessment</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Evaluation of urine specimen by dipstick</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collection of concomitant medications</measure>
    <time_frame>6 Weeks</time_frame>
    <description>questionnaire at each visit to collect concomitant medications taken</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Seborrheic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Omiganan Topical Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omiganan 1.75%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketoconazole Topical Cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ketoconazole 2.0%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omiganan</intervention_name>
    <description>Omiganan Topical Gel</description>
    <arm_group_label>Omiganan Topical Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole</intervention_name>
    <description>Ketoconazole Cream</description>
    <arm_group_label>Ketoconazole Topical Cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vehicle</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects with mild to moderate facial SD (IGA 2 or 3), â‰¥18 years of
             age, inclusive. The health status is verified by absence of evidence of any clinical
             significant active or uncontrolled chronic disease other than SD following a detailed
             medical history, a complete physical examination including vital signs, 12-lead ECG,
             hematology, blood chemistry, virology and urinalysis;

          -  Confirmed SD diagnosis by dermatologist

          -  Significant facial SD affected area as judged by the investigator or medically
             qualified designee

          -  Able to participate and willing to give written informed consent and to comply with
             the study restrictions;

          -  Willing to refrain from using other SD treatments in the local treatment area

          -  Subjects and their partners of childbearing potential must use effective
             contraception, for the duration of the study and for 3 months after the last dose.

        Exclusion Criteria:

          -  Any current and / or recurrent clinical significant skin condition other than SD;

          -  Ongoing use of prohibited SD medication. Washout periods prior to baseline are as
             follows;

               1. Topical steroids, antibiotics, antifungals or other topical (OTC) therapies: 2
                  weeks

               2. Systemic steroids, antibiotics, antifungals or other systemic therapies: 4 weeks;

               3. Phototherapy: 3 weeks;

               4. Regular use of shampoo for the treatment of PC (including but not limited to OTC
                  zinc pyrithione shampoo), soap for the treatment of seborrheic dermatitis: 2
                  weeks

               5. Changing a soap, method for daily facial and hair washing: 1 week

          -  Known hypersensitivity to the compounds or excipients of the compounds;

          -  Tanning due to sunbathing, excessive sun exposure or a tanning booth within 3 weeks of
             enrollment;

          -  Pregnant, a positive pregnancy test, intending to become pregnant, or breastfeeding;

          -  Participation in an investigational drug or device study within 3 months prior to
             screening or more than 4 times in the past year;

          -  Loss or donation of blood over 500 mL within three months (males) or four months
             (females) prior to screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Rissmann, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Human Drug Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Rissmann, PhD</last_name>
    <phone>+ 31 (0) 71 5246 400</phone>
    <email>clintrials@chdr.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre for Human Drug Research</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Rissmann, PhD</last_name>
      <phone>+ 31(0) 71 5246 400</phone>
      <email>clintrial@chdr.nl</email>
    </contact>
    <investigator>
      <last_name>Robert Rissmann, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>September 25, 2018</study_first_submitted>
  <study_first_submitted_qc>September 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2018</study_first_posted>
  <last_update_submitted>April 29, 2019</last_update_submitted>
  <last_update_submitted_qc>April 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Seborrheic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

